Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs Johnson & Johnson — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $129.17, while Johnson & Johnson trades at $259.89 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while ARK Autonomous Technology & Robotics ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ARKQ | JNJ | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $267.24 |
52-Week Low | $95.28 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $129.39, up 1.17% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting Cathie Wood's continued bets on disruptive tech like SpaceX and Joby Aviation. Its portfolio has shifted toward quality and momentum names, blending defense stocks for resilience.
Outlook remains positive for long-term growth in AI and robotics, but high RSI levels suggest near-term overbought risk. Key risks include tech sector volatility and reliance on speculative holdings. Analysts view it as a hold with accumulation opportunities during pullbacks.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
